B2Prime and cTrader Expand Trading Opportunities with a New Partnership
10.6.2024 14:18:00 EEST | Business Wire | Press release
B2Prime, a leading global multi-asset and multi-market Prime of Prime liquidity provider, and Spotware, a premier and innovative trading platform provider, have announced a strategic partnership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610848632/en/
B2Prime, a Prime of Prime multi-asset liquidity provider, and cTrader, Spotware's flagship trading platform, have established a strategic partnership to expand trading opportunities. (Graphic: Business Wire)
The cTrader platform by Spotware is renowned for its advanced features that cater to professional traders:
Clear and stunning UI → Visually appealing and comprehensive user interface with a possibility for deep customisation.
Multi-asset trading without latency → A diverse range of supported asset classes alongside lightning-fast order entry and execution.
Depth of market (DOM) → Level II pricing empowers traders to evaluate market sentiment and anticipate potential price movements with higher accuracy.
Top availability → cTrader offers cross-platform accessibility with its Desktop, Mac, Web and Mobile (iOS and Android) apps.
Advanced risk management → cTrader users are equipped with sophisticated protection tools to trade with confidence.
Algo trading solutions → Out-of-the-box ecosystem for algo trading, with cBots, indicators and plugins.
Social trading platform → cTrader Copy is an integrated platform where strategy providers and investors meet.
Nicholas Chrysochos, Executive Director of B2Prime, remarks:
"Numerous hedge funds, money managers, professional traders, algorithmic traders, systematic traders, and high-net-worth individuals have shown a keen interest in accessing our extensive liquidity pool. In response to this growing demand, we have chosen cTrader as the platform through which these clients can access our bespoke liquidity products across a wide range of jurisdictions. We are licensed by CySEC, allowing us to serve the entire EU market, and we also hold licenses in Mauritius and Seychelles. This strategic growth is part of our commitment to helping our clients excel in competitive global markets."
Currently, B2Prime has several outstanding platforms, namely OneZero, PrimeXM, now cTrader, and FIX API connectivity.
Ilia Iarovitcyn, CEO of Spotware Systems, comments:
“We are excited to continuously develop our liquidity provision network, expand the asset offering and enhance the reliability of our trading environment. Partnering with B2Prime contributes to delivering competitive pricing and an exceptional trading experience to our end users. With our cutting-edge technology and B2Prime’s strategic growth, we are confident in driving innovation and success for our clients globally.”
The collaboration between B2Prime and Spotware extends B2Prime’s range of services and significantly enhances cTrader’s liquidity offering, making it even more competitive. With a portfolio of over 200 instruments across six asset classes—FOREX, Crypto CFDs, Spot Indices, Precious Metals, Commodities, and NDFs—B2Prime offers one of the most comprehensive liquidity solutions on the market.
The company guarantees access to the deepest liquidity pools sourced from the most reputable providers, ensuring competitive spreads and swift execution. Additionally, B2Prime provides multi-currency prime margin accounts and an institutional tiered-margin approach.
Spotware is a global technology provider, successfully delivering cutting-edge fintech solutions and infrastructure for over 14 years. The company has cultivated a sophisticated network of 240+ brokers and prop firms. With a user base exceeding 4 million traders, cTrader, Spotware’s flagship platform, stands out for its unparalleled innovativeness and user-friendly UI, setting new standards across the industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610848632/en/
Contact information
B2Prime
info@b2prime.com
+357 25 582 192
Spotware
sales@spotware.com
+357 25 344 902
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 15:01:00 EEST | Press release
Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps, supplying inhibitors, biocides and PH control additives. Hyper scale datacenters require new type of cooling solutions. In today’s liquid-cooled data centers, coolant quality and water treatment is becoming a rising issue. Left unmanaged, chemistry drift quietly takes away cooling pe
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 15:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executing in “a structurally challenged print market.” Since our September letter, we’ve continued to actively engage with Xerox, including at the recent PRINTING United Expo in Las Vegas, and our conversations have been encouraging. We greatly appreciate the willin
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data include an oral proffered paper presentation on BeOne’s GPC3x4-1BB bispecific antibody, currently being studied in hepatocellular carcinoma (HCC) and first-in-human data for two investigational lung cancer assets, a CEA targeting antibody-drug conjugate (ADC), in CEA-expressing non-small cell lung cancer (NSCLC), and a brain-penetrant PRMT5 inhibitor in MTAP-deleted tumors, inclu
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Experts in Vienna19.10.2026 13:00:00 EEST | Press release
Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent challenge: transforming Europe's data centre energy landscape. We brought together leaders from across the data ce
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO ® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 12:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically relevant target in the treatment of moderate to severe ulcerative colitis.1 Results were presented during late-breaker and poster sessions at United European Gastroenterology (UEG) Week 2026 and published in the United European Gastroenterology Journal. “There has been increasing conversation about whether achieving deeper levels of remission – addressing both visible and microscopic inflammation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom